Policy & Regulation
Vial adds Dr Luke Nordquist to company's Oncology Scientific Advisory Board
4 August 2022 -

United States-based contract research organisation Vial announced on Wednesday that it has added Dr Luke Nordquist to the company's Oncology Scientific Advisory Board.

Nordquist, MD, FACP is serving as the CEO of the XCancer Research Network and founded the Urology Cancer Center & GU Research Network. He has become a global Oncology KOL due to his main role in ground-breaking clinical trials from Phase I-IV. He has been serving as the principal investigator on various urologic cancer studies including several first-in-world treatments.

Dr Nordquist said, 'My mission when I started as an Oncologist was to advance therapeutic developments in order to serve patients. XCancer and UCC were started to deliver on this mission. I'm excited to advise the Vial Oncology CRO team on the pain points that PIs and Oncology sites face in order to build an Oncology CRO that reimagines clinical trials through better technology and a new model cantered around speed and quality.'